Skip to contentA
Adaptimmune Therapeutics PLC
A
ADAPYAdaptimmune Therapeutics PLC Q1 2025 · 10-Q
Revenue$7.29M$7.29M+28.3% vs Q1 2024 Net Income-$47.58M-$47.58MN/M vs Q1 2024 EPS Diluted-$0.03-$0.03N/M vs Q1 2024 Operating Income-$45,733,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
Free Cash Flowderived-$67,795,000N/M Margins · derivedOperating margin-627.8%+239.8 pt vs Q1 2024
Net margin-653.2%+201.0 pt vs Q1 2024
ended Mar 31, 2025 · filed May 13, 2025 · 43 d after period end